A Phase I/IIa，Open-label, Single Ascending Dose and Dose-expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of YOLT-201 in Patients With Transthyretin Amyloidosis Polyneuropathy (ATTR-PN) or Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 23, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2026

Conditions

Transthyretin Amyloidosis PolyneuropathyTransthyrexin Amyloidosis Cardiomyopathy

Interventions

DRUG

YOLT-201

Infusion of YOLT-201 at Day 1

Trial Locations (3)

RECRUITING

Peking Union Medical College Hospital, Beijing

RECRUITING

The First Affiliated Hospital, School of Medicine, Zhejiang University, Hanzhou

RECRUITING

The Second Xiangya Hospital of Central South University, Changsha

All Listed Sponsors

lead

YolTech Therapeutics Co., Ltd

INDUSTRY